title: A pharmacological analysis of mice with a targeted disruption of the serotonin transporter.
abstract: BACKGROUND
  Partial or complete ablation of serotonin transporter (SERT) expression in mice leads to altered responses to serotonin receptor agonists and other classes of drugs.
  
  
  OBJECTIVE
  In the current report, we review and integrate many of the major behavioral, physiological, and neurochemical findings in the current literature regarding pharmacological assessments made in SERT mutant mice.
  
  
  RESULTS
  The absence of normal responses to serotonin reuptake inhibiting (SRI) antidepressants in SERT knockout (-/-) mice demonstrates that actions on SERT are a critical principle mechanism of action of members of this class of antidepressants. Drugs transported by SERT, (+)-3,4-methylenedioxymethamphetamine (MDMA) and 1-methyl-4-(2'-aminophenyl)-1,2,3,6-tetrahydropyridine (2'-NH(2)-MPTP), are also inactive in SERT -/- mice. Temperature, locomotor, and electrophysiological responses to various serotonin receptor agonists, including 8-hydroxy-2-(di-n-propylamino)-tetraline (8-OH-DPAT), ipsapirone, and RU24969, are reduced in SERT -/- mice, despite comparatively lesser reductions in Htr1a and Htr1b binding sites, G-proteins, and other signaling molecules. SERT -/- mice exhibit an approximately 90% reduction in head twitches in response to the Htr2a/2c agonist (+/-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI), associated with a profound reduction in arachidonic acid signaling, yet only modest changes in Htr2a and Htr2c binding sites. SERT -/- mice also exhibit altered behavioral responses to cocaine and ethanol, related to abnormal serotonin, and possibly dopamine and norepinephrine, homeostasis.
  
  
  CONCLUSIONS
  Together, these studies demonstrate a complex and varied array of modified drug responses after constitutive deletion of SERT and provide insight into the role of serotonin, and in particular, its transporter, in the modulation of complex behavior and in the pharmacological actions of therapeutic agents and drugs of abuse.
authors: Laboratory of Clinical Science, National Institute of Mental Health, National Institutes of Health, Building 10, Room 3D41, Bethesda, MD 20892, USA. mfox@mail.nih.gov
authors: Meredith A
authors: MA
authors: Fox
authors: Anne M
authors: AM
authors: Andrews
authors: Jens R
authors: JR
authors: Wendland
authors: Klaus-Peter
authors: KP
authors: Lesch
authors: Andrew
authors: A
authors: Holmes
authors: Dennis L
authors: DL
authors: Murphy
mesh_terms: D000818:Animals; D000928:Antidepressive Agents / Q000494:pharmacology; D001522:Behavior, Animal / Q000187:drug effects; D001831:Body Temperature / Q000187:drug effects; D000697:Central Nervous System Stimulants / Q000494:pharmacology; D004298:Dopamine / Q000378:metabolism; D000431:Ethanol / Q000494:pharmacology; D051379:Mice; D018345:Mice, Knockout; D009043:Motor Activity / Q000187:drug effects; D018817:N-Methyl-3,4-methylenedioxyamphetamine / Q000494:pharmacology; D012701:Serotonin / Q000378:metabolism; D018490:Serotonin Agents / Q000494:pharmacology*; D050486:Serotonin Plasma Membrane Transport Proteins / Q000235:genetics* / Q000378:metabolism; D017366:Serotonin Receptor Agonists / Q000494:pharmacology; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology; D005680:gamma-Aminobutyric Acid / Q000378:metabolism
chemical_list: D000928:Antidepressive Agents; D000697:Central Nervous System Stimulants; D004298:Dopamine; D000431:Ethanol; D018817:N-Methyl-3,4-methylenedioxyamphetamine; D012701:Serotonin; D018490:Serotonin Agents; D050486:Serotonin Plasma Membrane Transport Proteins; D017366:Serotonin Receptor Agonists; D017367:Selective Serotonin Reuptake Inhibitors; D005680:gamma-Aminobutyric Acid
references: Psychopharmacology (Berl). 2005 Jun;180(1):12-20
references: 15834538
references: Brain Res Dev Brain Res. 2004 Jun 21;150(2):151-61
references: 15158078
references: Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):2041-4
references: 9050901
references: Proc Natl Acad Sci U S A. 1993 Mar 15;90(6):2542-6
references: 7681602
references: Prog Neurobiol. 1998 Dec;56(6):613-72
references: 9871940
references: Pharmacol Biochem Behav. 2002 Apr;71(4):555-68
references: 11888547
references: Am J Hum Genet. 2006 May;78(5):815-26
references: 16642437
references: Neuropharmacology. 1985 Dec;24(12):1187-94
references: 2869435
references: Eur J Neurosci. 2003 Oct;18(8):2203-12
references: 14622181
references: Pharmacol Biochem Behav. 2002 Apr;71(4):533-54
references: 11888546
references: Br J Pharmacol. 1992 Sep;107(1):15-21
references: 1422568
references: Eur J Pharmacol. 2002 Jun 28;447(1):67-74
references: 12106804
references: Brain Res. 1997 Dec 19;778(2):338-45
references: 9459551
references: J Neurosci. 2004 Dec 1;24(48):10868-77
references: 15574737
references: Proc Natl Acad Sci U S A. 2005 Apr 12;102(15):5582-7
references: 15809439
references: Biol Psychiatry. 2007 Sep 15;62(6):669-79
references: 17306775
references: J Pharmacol Exp Ther. 2004 Feb;308(2):481-6
references: 14610240
references: Cell Mol Neurobiol. 1999 Aug;19(4):467-89
references: 10379421
references: Neuropsychopharmacology. 2004 Oct;29(10):1790-9
references: 15226739
references: J Neurosci. 2006 May 17;26(20):5554-64
references: 16707806
references: Anal Chem. 2005 Feb 1;77(3):818-26
references: 15679349
references: J Neurosci Res. 2003 Apr 15;72(2):250-8
references: 12672000
references: Biol Psychiatry. 2003 Nov 15;54(10):960-71
references: 14625138
references: Genes Brain Behav. 2003 Dec;2(6):365-80
references: 14653308
references: Neurosci Lett. 1997 May 9;227(1):13-6
references: 9178847
references: Mol Pharmacol. 2006 Dec;70(6):2052-63
references: 16985186
references: Neurosci Lett. 1999 Mar 5;262(2):113-6
references: 10203244
references: Mol Pharmacol. 1999 Jul;56(1):54-67
references: 10385684
references: Mol Psychiatry. 2007 Mar;12(3):247-57
references: 17146470
references: Behav Brain Res. 1996;73(1-2):277-80
references: 8788518
references: Alcohol Alcohol. 2003 Jul-Aug;38(4):386-9
references: 12814910
references: J Neural Transm (Vienna). 1997;104(11-12):1259-66
references: 9503271
references: J Pharmacol Exp Ther. 1999 Dec;291(3):999-1007
references: 10565817
references: Mol Pharmacol. 1993 Feb;43(2):271-6
references: 8429828
references: J Pharmacol Exp Ther. 1997 Aug;282(2):699-706
references: 9262333
references: Genes Brain Behav. 2007 Jun;6(4):389-400
references: 16939636
references: Neuropsychopharmacology. 2002 Dec;27(6):914-23
references: 12464448
references: Nature. 1996 Feb 15;379(6566):606-12
references: 8628395
references: J Neurosci Methods. 2004 Dec 30;140(1-2):169-81
references: 15589347
references: J Neurosci. 2001 Sep 1;21(17):6862-73
references: 11517274
references: Proc Natl Acad Sci U S A. 1987 Jun;84(12):4322-6
references: 3473503
references: Behav Pharmacol. 2006 May;17(3):271-87
references: 16572005
references: J Neurochem. 1993 Mar;60(3):1167-70
references: 8094744
references: Neurosci Lett. 2006 Jun 19;401(1-2):49-54
references: 16638624
references: Nat Rev Drug Discov. 2005 Sep;4(9):775-90
references: 16138108
references: Neuron. 2005 Apr 7;46(1):65-74
references: 15820694
references: Psychopharmacology (Berl). 1985;85(3):367-70
references: 3923523
references: Psychopharmacology (Berl). 1996 Aug;126(3):234-40
references: 8876023
references: Biol Psychiatry. 2003 Nov 15;54(10):953-9
references: 14625137
references: J Neurosci. 2000 Nov 1;20(21):7888-95
references: 11050108
references: J Neurosci. 2001 Mar 15;21(6):2178-85
references: 11245702
references: Neuroscience. 1998 Oct;86(3):729-37
references: 9692713
references: Nature. 1977 Apr 21;266(5604):730-2
references: 559941
references: Eur J Neurosci. 2000 Jul;12(7):2299-310
references: 10947809
references: J Neural Transm Gen Sect. 1994;95(2):157-62
references: 7865169
references: Expert Opin Investig Drugs. 1999 Apr;8(4):417-41
references: 15992089
references: J Neurosci. 2003 Oct 1;23(26):8836-43
references: 14523084
references: J Neural Transm (Vienna). 2004 Jan;111(1):27-35
references: 14714213
references: J Pharmacol Exp Ther. 1999 Jan;288(1):98-106
references: 9862759
references: J Neurosci Res. 2003 Mar 1;71(5):701-9
references: 12584728
references: Br J Pharmacol. 2003 Mar;138(6):1119-28
references: 12684268
references: Brain Res Dev Brain Res. 2001 Jan 31;126(1):125-9
references: 11172895
references: Science. 2004 Oct 29;306(5697):879-81
references: 15514160
references: Sleep Med Rev. 2002 Oct;6(5):341-51
references: 12531125
references: Rev Neurosci. 2000;11(1):53-8
references: 10716655
references: J Pharmacol Exp Ther. 2002 Nov;303(2):527-33
references: 12388632
references: Pharmacol Biochem Behav. 1992 May;42(1):45-7
references: 1528946
references: Eur J Pharmacol. 1997 Jun 11;328(2-3):153-62
references: 9218697
references: Trends Cogn Sci. 2006 Apr;10(4):182-91
references: 16530463
references: J Neurosci. 2001 Feb 1;21(3):884-96
references: 11157075
references: Neurosci Lett. 2003 May 22;342(3):175-8
references: 12757893
references: Int J Neuropsychopharmacol. 2006 Jun;9(3):307-17
references: 16035958
references: Brain Res. 2002 Jun 28;942(1-2):109-19
references: 12031859
references: Neuropsychopharmacology. 2002 Sep;27(3):380-90
references: 12225695
references: Neuroscience. 2006 Jun 19;140(1):321-34
references: 16542782
references: Mol Pharmacol. 2004 Sep;66(3):718-27
references: 15322265
references: Brain Res. 2001 Feb 16;892(1):176-92
references: 11172762
references: Neuroreport. 2003 Feb 10;14(2):233-8
references: 12598736
references: Behav Genet. 2006 Mar;36(2):163-72
references: 16402281
references: J Clin Psychiatry. 1998;59 Suppl 15:4-12
references: 9786305
references: Endocrinology. 2002 Dec;143(12 ):4520-6
references: 12446578
references: J Neurosci. 2006 Jun 14;26(24):6431-8
references: 16775130
references: Am J Med Genet. 2000 Apr 3;96(2):202-16
references: 10893498
references: Neuropharmacology. 2005 Nov;49(6):798-810
references: 16183083
references: Brain Res. 1996 Jun 10;724(1):84-8
references: 8816259
references: J Neurosci. 2002 Nov 1;22(21):9635-42
references: 12417689
references: Mol Pharmacol. 1998 Apr;53(4):649-55
references: 9547354
references: J Neurochem. 2003 Mar;84(6):1256-65
references: 12614326
references: Neuropsychopharmacology. 2003 Dec;28(12):2077-88
references: 12968128
references: J Neurochem. 2003 Jul;86(1):210-9
references: 12807440
references: Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7699-704
references: 9636213
references: Neuroscience. 2002;115(1):153-61
references: 12401330
references: J Neurosci. 2006 Aug 30;26(35):8955-64
references: 16943551
references: Br J Pharmacol. 1991 Aug;103(4):1857-64
references: 1833017
references: J Pharmacol Exp Ther. 2001 Mar;296(3):987-95
references: 11181933
references: J Neurochem. 2004 May;89(4):886-96
references: 15140188
references: Alcohol Clin Exp Res. 2006 Dec;30(12):1957-65
references: 17117959
references: Psychopharmacology (Berl). 2002 May;161(2):160-7
references: 11981596
references: Crit Rev Neurobiol. 1999;13(4):317-56
references: 11028680
references: J Pharmacol Exp Ther. 1993 Dec;267(3):1432-9
references: 8263805
references: J Neurosci Methods. 2006 Jun 30;154(1-2):245-55
references: 16472867
references: Science. 1996 Nov 29;274(5292):1527-31
references: 8929413
references: J Neurochem. 1998 Mar;70(3):932-9
references: 9489712
references: Eur J Pharmacol. 1993 Dec 7;250(2):215-21
references: 8112382
references: Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5300-5
references: 11320258